Latest Genentech Inc. Stories
FAIRFIELD, N.J., Feb. 11, 2011 /PRNewswire-USNewswire/ -- The Healthcare Businesswomen's Association (HBA) today announced that it has named Ian T. Clark, Genentech's chief executive officer and head of North American commercial operations, as its 2011 Honorable Mentor.
SUNNYVALE, Calif., Nov. 8, 2010 /PRNewswire-FirstCall/ -- Pharmacyclics, Inc.
LONDON, July 12, 2010 /PRNewswire/ -- MRC Technology (UK) announced today that it has entered into an agreement with Genentech, Inc., a wholly owned member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) for an exclusive licence to a series of small molecule drug candidates for the potential treatment of neurological disease. This is the first small molecule chemistry programme to come out of MRC Technology's Centre for Therapeutics Discovery (CTD) and the first major small molecule...
NEW YORK, Sept.
NEW YORK, Sept.
RICHMOND, Calif., June 29 /PRNewswire-FirstCall/ -- Sangamo BioSciences, Inc.
VANCOUVER, June 15 /PRNewswire-FirstCall/ - QLT Inc.
The U.S. Food and Drug Administration says Genentech Inc.
CHICAGO, April 8 /PRNewswire/ -- "Options News," hosted by Carrie Long and www.ONN.tv Senior Market Specialist Jared Levy, reviews futures and overseas trading, discusses the latest economic news, and analyzes notable options activity. (Logo: http://www.newscom.com/cgi-bin/prnh/20090323/AQM046LOGO) Today's program dissects Alcoa's (AA) earnings report, which unofficially kicked off earnings season Tuesday night.
An approach that involves mixing two drugs to battle advanced cases of colon cancer appears to make the condition worse, a new study finds.
- A transitional zone between two communities containing the characteristic species of each.